NCT02675829 2026-03-04
Trial of Ado-Trastuzumab Emtansine for Patients With HER2 Amplified or Mutant Cancers
Memorial Sloan Kettering Cancer Center
Phase 2 Active not recruiting
Clinical Trials
3 trialsNCT02452554 2022-01-13
Lorvotuzumab Mertansine in Treating Younger Patients With Relapsed or Refractory Wilms Tumor, Rhabdomyosarcoma, Neuroblastoma, Pleuropulmonary Blastoma, Malignant Peripheral Nerve Sheath Tumor, or Synovial Sarcoma
Children's Oncology Group
Phase 2 Completed
NCT02999672 2019-08-28
KAMELEON
Hoffmann-La Roche
Phase 2 Completed